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The status of p53 was investigated in breast tumours
arising in germ-line carriers of mutant alleles of BRCA1
and BRCA2 and in a control series of sporadic breast
tumours. p53 expression was detected in 20/26 (77%)
BRCA1-, 10/22 (45%) BRCA2-associated and 25/72
(35%) grade-matched sporadic tumours. Analysis of p53
sequence revealed that the gene was mutant in 33/50
(66%) BRCA-associated tumours, whereas 7/20 (35%)
sporadic grade-matched tumours contained p53 mutation
(P50.05). A number of the mutations detected in the
BRCA-associated tumours have not been previously
described in human cancer databases, whilst others occur
extremely rarely. Analysis of additional genes, p16INK4,
Ki-ras and b-globin revealed absence or very low
incidence of mutations, suggesting that the higher
frequency of p53 mutation in the BRCA-associated
tumours does not re¯ect a generalized increase in
susceptibility to the acquisition of somatic mutation.
Furthermore, absence of frameshift mutations in the
polypurine tracts present in the coding sequence of the
TGF b type II receptor (TGF b IIR) and Bax implies
that loss of function of BRCA1 or BRCA2 does not
confer a mutator phenotype such as that found in
tumours with microsatellite instability (MSI). p21Waf1
was expressed in BRCA-associated tumours regardless
of p53 status and, furthermore, some tumours expressing
wild-type p53 did not express detectable p21Waf1. These
data do not support, therefore, the simple model based
on studies of BRCA7/7 embryos, in which mutation of
p53 in BRCA-associated tumours results in loss of
p21Waf1 expression and deregulated proliferation. Rather,
they imply that proliferation of such tumours will be
subject to multiple mechanisms of growth regulation.
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Introduction
Inheritance of mutant alleles of the breast cancer
susceptibility genes BRCA1 and BRCA2 confers a
substantial risk of developing breast, ovarian and some
other cancers (Mikki et al., 1994; Wooster et al., 1995).
BRCA1 and BRCA2 have numerous similarities
(Zhang et al., 1998). Tumorigenesis in carriers of
germ-line mutations in BRCA1 and BRCA2 is
invariably accompanied by loss of the wild-type allele
(Smith et al., 1992; Neuhausen and Marshall, 1994;
Collins et al., 1995; Gudmundsson et al., 1995; Kelsell
et al., 1996) suggesting that the proteins encoded by the
two genes operate as tumour suppressors. An
increasing-body of evidence favours a role for both
BRCA1 and BRCA2 in cellular response to DNA
damage (Connor et al., 1997; Scully et al., 1997; Patel
et al., 1998). It is postulated that the BRCA genes act
as caretakers, functioning to maintain genomic
stability, rather than as gatekeepers which regulate
cellular proliferation (Brugarolas and Jacks, 1997;
Kinzler and Vogelstein, 1997). Embryos homozy-
gously deleted for BRCA1 or 2 are inviable, cells
undergoing a p21Waf1-mediated growth arrest at around
day 5 ± 6 (Hakem et al., 1996; Suzuki et al., 1997). This
lethality is partially reversed by breeding into a p53 or
p21Waf1 null background (Hakem et al., 1997; Ludwig et
al., 1997). Paradoxically, tumours arising in carriers of
BRCA1 mutations are frequently highly proliferative,
despite being functionally null for BRCA1 (Eisenger et
al., 1996; Marcus et al., 1996; Johannsson et al., 1997).
The molecular basis for this is not known. Analysis of
®broblasts derived from mice homozygous for a
truncating mutation in BRCA2 has revealed a
proliferation defect associated with p53-dependent
induction of p21Waf1 expression, and a DNA repair
defect (Connor et al., 1997). In another study, mouse
embryo ®broblasts carrying BRCA2 truncations, were
shown to be signi®cantly more sensitive to UV
irradiation and the alkylating agent methylmethanesul-
phonate than wild-type controls, leading to the
suggestion that BRCA2 may be associated with a
nucleotide excision repair pathway (Patel et al., 1998).
However, it is not known whether these defects occur
in tumours arising in carriers of germline mutant alleles
of BRCA1 and BRCA 2.
In sporadic breast cancer the frequency of p53
mutation is 20 ± 40%, the proportion of mutant
tumours increasing with higher grade. In a previous
study using DNA extracted from paran sections, p53
mutations were reported to occur at high frequency in
familial tumours (of unknown BRCA status) but not
sporadic breast tumours (Glebov et al., 1994).
Furthermore, analysis of a small series of breast and
ovarian tumours arising in carriers of mutant BRCA1
alleles revealed a high incidence of p53 mutation
(Crook et al., 1997). In the present study we have
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investigated the status of p53 in a larger series of
BRCA1- and BRCA2-associated breast carcinomas
and in a group of sporadic breast tumours matched
for grade, and have compared both the frequency and
nature of the p53 mutations detected in the two
groups.
Results
The expression and structure of p53 was examined in
50 tumours arising in carriers of germ-line mutations in
BRCA1 (28 tumours) and BRCA2 (22 tumours). The
germ-line mutations in these families have been
described previously (Gayther et al., 1995, 1997). To
control for a potentially biasing eect of grade, a series
of sporadic grade 3 breast tumours, previously
characterized by the Breast Cancer Linkage Consor-
tium (1997), was analysed in parallel.
Expression of p53 in BRCA1- and BRCA2-associated
breast tumours
Expression of p53 in sporadic and familial tumours
was analysed by immunocytochemistry (IC) in paran
sections of formalin-®xed tissues, using the DO-1
antibody. 20/26 (77%) of BRCA1-, 10/22 (45%) of
BRCA2-associated tumours and 25/72 (35%) of grade-
matched sporadic tumours were positive (Figure 1 and
Table 1). In all cases of BRCA1- and BRCA2-
associated tumours where ductal carcinoma in situ
(DCIS) was also present in the tissue sections
examined, the p53 immunostaining detected in
invasive tumour tissue was also present in the DCIS.
In no section examined was p53 staining observed in
normal tissue. Detection of p53 by IC in breast
tumours frequently re¯ects stabilization due to muta-
tion (Visscher et al., 1996). The absence of immuno-
cytochemically detectable p53 in normal breast tissue in
our study therefore implies somatic acquisition, rather
than germline inheritance, of p53 mutation. It is
estimated, however, that 10 ± 15% of mutants do not
give rise to stabilized protein and that p53 becomes
stabilized (and thereby detectable) in some breast
tumours despite being wild-type (Visscher et al.,
1996). We therefore analysed the sequence of p53 in
the sporadic and BRCA-associated tumours.
p53 is mutant at high frequency in BRCA-associated
tumours
Genomic DNA was extracted from formalin-®xed,
paran-embedded tumour sections from 28 BRCA1-,
22 BRCA2-associated and 20 grade 3 sporadic tumours
and used for analysis of the sequence of various genes.
For p53 analysis, DNA was subjected to single strand
conformation polymorphism analysis (SSCP), cloning
and sequencing of each p53 exon (Visscher et al.,
1996). However, when it was observed in preliminary
studies that p53 mutation was common in the BRCA1-
and BRCA2-associated tumours, the coding sequence
of p53 was then analysed in its entirety in each BRCA-
associated and sporadic tumour by sequencing at least
12 independent plasmid clones for each exon for each
tumour, irrespective of the presence or not of SSCP
mobility shifting. In the BRCA1-associated tumours,
p53 mutations were detected in 19/28 tumours
analysed, two of which were negative by IC (Table
1). In the case of the BRCA2-associated tumours, 14/
22 tumours were mutant for p53 these being all nine
tumours positive by IC and ®ve negative by IC (Table
1, Figure 2). Similar sequencing analysis of DNA
extracted from paran sections of 20 sporadic grade 3
tumours revealed single missense mutations in 7/20
tumours (Table 1). The dierence in p53 mutation
frequency between the sporadic and BRCA-associated
tumours was statistically signi®cant (P50.05).
Multiple p53 mutations occur in some BRCA-associated
but not sporadic breast tumours
Sequencing analysis revealed that ®ve BRCA1-asso-
ciated and three BRCA2-associated tumours contained
two p53 mutations. One BRCA1-associated tumour
and one BRCA2-associated tumour contained three
independent mutations (Table 1). In four BRCA1- and
three BRCA2-associated tumours with two mutations,
a dierent coding change occurred with the identical
silent, second mutation (codon 211 ACT4ACC). In
the informative tumours, sequencing of multiple
plasmid clones revealed that the mutations usually
occurred on the same allele (Figure 2a). Thus in the
BRCA2 tumour with three mutations (202R4S, 214
H4R and 219 P4H), all three occurred on the same
allele. Similarly, in the two informative BRCA2
Figure 1 Immunocytochemical analysis of p53 expression in BRCA1-associated breast cancer. (a) positive tumour: (b) negative tumour. The
scale bars are equivalent to 10 mm
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tumours with two mutations (202R4S, 211 Sil.) and
(220Y4H, 211 Sil.), both mutations were on the same
allele. Further sequence analysis of multiple indepen-
dent plasmid clones from these two tumours identi®ed
numerous cases in which only the mutation resulting in
the coding change (202R4S or 220Y4H) was present.
However, no clone was observed in which the silent
mutation at codon 211 alone was detected, implying
that it arose subsequent to the coding mutation (Table
1). Previous studies using DNA extracted from paran
sections have reported multiple p53 mutations in
familial tumours (of unknown BRCA status) but not
sporadic breast tumours. To further verify that the
mutations in the present study were not artefacts
attributable to tissue ®xation or contamination, and to
con®rm that they were somatically acquired and not
germ-line or polymorphisms, microdissected tumour,
DCIS and normal from selected tissue sections were
analysed for the presence of mutations. In each of the
analysed cases, the coding mutations originally
detected in DNA from undissected tissue sections
were also identi®ed in the microdissected tumour and
the single case of DCIS (Table 2). In the two cases
analysed where the tumour contained a non-coding
change at codon 211, in addition to coding changes,
sequencing analysis did not detect the codon 211
change in the microdissected DCIS. These observations
are consistent with (i) absence of p53 expression in
normal tissue present in any of the tissue sections
analysed (ii) the presence of immunocytochemically
detectable p53 protein in cases of DCIS where the
associated tumours were also positive for p53
expression (iii) somatic acquisition rather than germ-
line inheritance of the p53 sequence changes.
Absence of mutator phenotype in BRCA-associated
tumours
The frequency and occasional multiplicity of p53
mutation suggested that loss of BRCA1 and BRCA2
function might confer a generalized increase in
sensitivity to somatic mutation of cellular genes. To
investigate this possibility, we performed analysis of
the structure of additional genes which are rarely
mutant (Ki-ras) or almost never mutant (p16INK4) in
sporadic breast cancer. We also analysed a gene in
which mutation could not provide a selective
advantage (b-globin). Consistent with previous stu-
dies, no mutations were detected in p16INK4 in paran-
extracted DNA from the sporadic grade 3 tumours,
nor in any of the BRCA-associated tumours. The
proposed absence of p16INK4 mutations in BRCA
tumours was further con®rmed by direct sequencing
in 12 of the BRCA1-associated and 12 of the BRCA2-
associated tumours. In the case of the Ki-ras oncogene
which is often mutant in pancreatic carcinomas (Bos,
1987), but only rarely in sporadic breast tumours, a
codon 12 mutation (GGT4GAT, Gly4Asp) was
detected in one BRCA2-associated tumour, whereas
13 further tumours analysed (eight BRCA1 and ®ve
BRCA2) did not contain activating mutations at these
sites. Mutation at this codon has been previously
detected in sporadic breast cancer and in a breast
carcinoma cell line (Prosperi et al., 1990). Furthermore,
this frequency of Ki-ras mutation is comparable to that
reported in sporadic breast tumours (Rochlitz et al.,
1989; Clark et al., 1995). Finally a 268 bp fragment of
the b-globin gene was analysed by SSCP in each of the
BRCA1 and BRCA2 tumours and the sporadic grade 3
breast tumours. No mobility shifts indicative of
mutation were detected. Because the incidence of p53
mutations suggested the possibility of a mutator
phenotype, we analysed the poly(A)10 tract of TGF-
bIIR and the poly(G)8 tract of Bax in the BRCA-
associated tumours, since studies of human tumours
with microsatellite instability (MSI) arising in a
classical mutator background have revealed frameshift
mutations within these regions of each gene. No
aberrant mobility bands suggestive of frameshift
mutation were observed in any of 28 tumours
analysed (16 BRCA1, 12 BRCA2).
Expression of p21WAF1 occurs in BRCA1- and BRCA2-
associated tumours irrespective of p53 status
Studies of embryos deleted for both BRCA2 and p53,
or BRCA2 and p21Waf1, have revealed that development
progresses to a signi®cantly later stage (in such double
knockouts) than in BRCA27/7 embryos which
undergo cell cycle arrest at day 5 ± 6. This suggests
Figure 2 Sequence analysis of p53 in BRCA-associated breast
tumours. (a) Presence of two p53 mutations in the same allele of
p53 in BRCA1-associated tumour. The sequence changes at
codon 224 gAg4gAC and codon 211 ACT4ACC are arrowed;
(b) Tandem CC4TT transition at codons 247/248 (arrowed in
lane MT) in BRCA2-associated tumour. The wild-type sequence
(WT) is also shown; (c) Codon 199 mutation (ggA4AgA)
arrowed in BRCA1-associated tumour; (d) Silent sequence
change at codon 170 ACg4ACA in BRCA1-associated tumour
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Table 1 p53 mutations in tumours arising in carriers of mutant BRCA1/2 alleles and grade-matched sporadic breast tumours
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that loss of the p53-dependent, p21Waf1 mediated G1-S
checkpoint confers partial rescue of the cell cycle arrest
consequent to abrogation of BRCA1 or BRCA2
function. To determine whether expression of p21Waf1
is aected by p53 status in BRCA1- and BRCA2-
associated tumorigenesis, expression was analysed in
tumours by IC. In the 20 sporadic grade 3 tumours,
expression was absent or at extremely low levels
irrespective of p53 status or expression, even in the
three tumours which expressed signi®cant wild-type
p53 (Table 1). In the case of the BRCA1-associated
tumours, expression of p21Waf1 was detected in 9/26
tumours analysed, these comprising four wild-type and
®ve mutant for p53. Three tumours wild-type for p53
did not express p21Waf1 despite having high levels of p53
protein (Table 1). Analysis of BRCA2-associated
tumours revealed expression of p21Waf1 in 5/22
tumours including three tumours mutant for p53
(Table 1). The highest expression of p21Waf1 was
observed in two of the eight BRCA2-associated
tumours which retained wild-type p53 (Table 1).
However, in these tumours p21Waf1 expression was not
detected in every tumour cell. Rather, intense
expression was observed in some cells, whereas
expression was either much reduced or absent in other
cells. Of the remaining six BRCA2 tumours wild-type
Table 2 p53 status of microdissected BRCA1-associated tissues





































aTotal number of clones in which coding change was detected. bNumber of clones in which non-coding change was detected with coding change.
cCannot be determined whether these changes occur together on same allele. dNumber of clones in which silent mutation was detected. N/D:
Not done (no DCIS in section)
Table 1 continued































































































































































aMutations occurring on same allele; bDuctal Carcinoma in situ; cMutations occurring on dierent alleles; dCannot be determined whether
mutations are on the same allele; eMutation previously reported (Crook et al., 1997); N/D: not determined
p53 mutations in familial breast cancer
T Crook et al
1685
for p53, only a single tumour expressed detectable p53
protein and none expressed p21Waf1 (Table 1). Taken
together, these data imply that, as in sporadic breast
and other tumours, p21Waf1 expression is induced in
some cases by p53-independent mechanisms.
Eect of p53 mutation on mitosis in BRCA1- and
BRCA2-associated tumours
The higher frequency of p53 mutation in the BRCA1
and BRCA2 tumours than in sporadics implies some
form of selective pressure. Although abrogation of
p21Waf1 expression does not appear to be the basis for
this, we sought to establish whether proliferation was
aected by p53 status by determining mitotic fraction
in BRCA-associated tumours mutant or wild-type for
p53. These analyses suggested that no clear relationship
exists between p53 mutation and proliferation (Table
1). For example, although mitosis is higher in some
tumours with mutant p53 in certain families (see for
example family B186), in other families mitotic fraction
was not elevated despite the presence of mutation. For
example in family B135, two of the three analysed
tumours retained wild-type p53 and exhibited an
extremely low mitotic fraction. In the third tumour
this extremely low proliferation was unaected by p53
mutation (codon 240R4S). Taken together, with the
analysis of p21Waf1 expression, these results are not
consistent with a model in which p53 mutation simply
re¯ects a requirement to abrogate a p21Waf1-dependent
proliferation block.
Discussion
In this study we demonstrate that p53 is mutant in a
higher proportion of BRCA1- and BRCA2-associated
breast tumours than in a series of sporadic breast
tumours matched for grade. The higher frequency
implies that mutation in p53 may have a role in
tumorigenesis in a proportion of the BRCA1- and
BRCA2-associated tumours in the present series.
However, the presence of a signi®cant number of
tumours which retain wild-type p53 and of a number
of tumours which express p21Waf1, suggests that neither
mutation of p53 nor loss of p21Waf1 expression is
required for BRCA-associated tumorigenesis.
The identity of the p53 mutations detected in both
BRCA1- and BRCA2-associated breast tumours is
most unusual and of interest in comparison with
numerous previous analyses of p53 in human cancer
in general, and in breast cancer speci®cally. Although
some of the mutants, such as 163Y4N, have been
previously documented in human breast cancer, a
signi®cant number have not been described. For
example, analysis of the IARC human cancer p53
mutation database revealed codon 211 mutations in
occasional tumours, but the ACT4ACC mutation
detected in the BRCA-associated tumours herein is not
present. Similarly, mutation at codon 150 is extremely
rare, being reported in only three cases, two of which
involve deletion. The ACA4ATA mutation we have
observed is the ®rst report of this sequence change, and
only the second observation of any missense mutation
at this codon in human cancer. A third example of an
apparently previously unobserved mutation is the
codon 202 CGT4AGT change we have detected in
three BRCA2-associated tumours. Although mutations
at codon 202 have been occasionally described, the
CGT4AGT mutation has not. Yet another example is
at codon 155. Ten point mutations at this codon are in
the IARC database, of which ®ve are ACC4CCC, two
are ACC4GCC, two ACC4AAC and one
ACC4ACT. The mutation detected in the BRCA2-
associated tumour in our study, ACC4ATC, has not
been previously described. Similarly, 11 point muta-
tions at codon 197 are present in the database, yet the
GTG4TTG mutation observed in a BRCA1-asso-
ciated tumour in the present study has not been
described. Additionally, in some tumours, mutations
were detected which are exceedingly rare in human
cancer. One such is the codon 199 change
GGA4AGA. This mutation occurs only once, this
being in a Wilm's tumour, in the IARC database. A
second, and related, observation of interest from our
work is the occurrence of p53 mutations in BRCA-
associated breast tumours which have previously only
been reported in cutaneous tumours. The most striking
example of this is the presence of a CC-TT tandem
transition at codons 247, 248 in one BRCA1- and one
BRCA2-associated tumour. Previously, such tandem
mutations at pyrimidine dimers have been described
exclusively, with a single exception, in cutaneous
neoplasia, their presence being attributed to produc-
tion of photolesions between adjacent pyrimidine bases
by UVB and subsequent impaired repair of the lesion
(Hutchinson, 1994). The observation of such sequence
changes in familial breast cancer, although most
unexpected, may result from exposure to oxidising or
other mutagenic agents which act with increased
eciency in cells with impaired DNA repair function
(Reid and Loeb, 1993). This hypothesis is strengthened
by the observation of the mutation TTT4TCT at
codon 212 in 2 BRCA1-associated tumours. Point
mutation at this codon is rare in human tumours, the
change TTT4TTA being reported in just three
tumours in the IARC database. Only a single other
codon 212 mutation is represented on the IARC
database, this being TTT4TCT in a skin tumour.
The recent demonstration that mouse ®broblasts with
truncated BRCA2 are more sensitive to UV irradiation
than controls (perhaps due to defective nucleotide or
base excision repair) is clearly of interest in the context
of this observation (Patel et al., 1998). Previous studies
of sporadic breast cancer have revealed three codons at
which mutation most commonly occurs: 175, 248 and
273 (Levine et al., 1994; Hollstein et al., 1994). Two
BRCA1-associated and one BRCA2-associated tumour
contained mutation at these `hot spot' codons, these
being the tandem 247, 248 CC4TT mutation alluded
to above in two cases and a single CGG4TGG
transition at codon 248 in one BRCA1 tumour. The
biological signi®cance of the unusual spectrum of p53
changes, and the mechanism underlying their presence
in BRCA-associated but not sporadic breast cancer
requires additional study. The presence of multiple p53
mutations, some of which were non-coding, was
described in by Glebov et al. (1994) in a study of
familial breast tumours of unknown BRCA status and
we now demonstrate multiple mutations in eight of the
BRCA1 and four of the BRCA2-associated tumours.
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The explanation for the multiple mutations is not clear.
However, it is noteworthy that in tumours with both
coding and silent mutations, the coding mutation is
clearly acquired before the silent change. It is not
possible from the present data to determine whether
loss of the wild-type BRCA allele precedes somatic
acquisition of p53 mutation or vice versa. The relatively
high frequency of mutation and presence of multiple
p53 mutations in some tumours is consistent with a
generalised increase in sensitivity to acquisition of
somatic gene mutations in BRCA-associated tumour-
igenesis. To address this possibility, we performed
sequence analysis of ®ve additional genes. We analysed
two genes in which mutation confers growth advantage
(Ki-ras by gain of function, p16INK4 by loss of
function), but which are infrequently mutant in
sporadic breast cancer, and it was reasoned that
mutation in either would be likely to confer a selective
advantage to cells in which they occur and thereby
favour their retention in tumour progression. However,
our analysis did not reveal a frequency of mutation in
either BRCA1- or BRCA2-associated tumours above
that observed in sporadic breast tumours of similar
grade. Thus, no mutations were detected in p16INK4 in
any of the familial tumours analysed, as has previously
been demonstrated in sporadic breast tumours (Xu et
al., 1994; Quesnel et al., 1995) and veri®ed in this
study. Similarly, analysis of Ki-ras revealed only a
single codon 12 mutation in 14 analysed tumours. Both
the identity and frequency of this change is consistent
with previous studies of ras genes in breast cancer
(Clark and Der, 1995). The absence of mutation in
globin further argues against a global increase in
mutation frequency in BRCA1- and BRCA2-associated
tumours. The presence of a mutator phenotype, similar
to that observed in Hereditary Non-Polyposis Colon
Cancer (HNPCC) and gastric carcinomas was investi-
gated by searching for frameshift mutations in TGF-b
type IIR and Bax. Mutations in polypurine tracts
within these genes have been reported in human
tumours, such as gastric carcinoma, with MSI
(Markowitz et al., 1995; Parsons et al., 1995; Chung
et al., 1997). However, the absence of any such changes
in the BRCA-associated tumours in the present series
implies that a classical mutator phenotype is not
present in BRCA-associated tumours. Consistent with
this observation, we failed to observe instability in
several microsatellites in the same tumours (data not
shown). Taken together, these results suggest that the
high frequency of p53 mutation is not the result of a
mutator phenotype.
Given the apparent absence of a global mutator
phenotype in BRCA1- and BRCA2-associated tumours,
the implication of our data is, therefore, that selective
pressure to abrogate one or more of the wild-type
functions of p53, or to acquire some gain of function
phenotype, (at least in some tumours) underlies the
increased mutation frequency. Neither the expression of
p21Waf1 in a signi®cant number of tumours mutant for
p53 nor the absence of a clear relationship between p53
status and proliferation is consistent with the hypothesis
that selection for p53 mutation in such tumours simply
re¯ects a requirement to abrogate a p21Waf1-dependent
G1 block. The presence of a signi®cant proportion of
tumours which retain (and in some cases express) wild-
type p53 further refutes this hypothesis. Taken together,
therefore, our data imply that proliferation of BRCA
tumours, like sporadic breast cancers, is subject to
regulation by multiple factors, genetic, epigenetic and
hormonal, rather than by activation of a single cell cycle




The tumours analysed in this study arose in con®rmed
carriers of germ-line mutant alleles of BRCA1 and BRCA2
and were identi®ed from databases compiled by Professor
M Stratton. The cases were unselected and were all of
those available to us where paran blocks of the tumours
had been collected into the department and sections had
been taken for immunohistochemistry and thick sections
taken for DNA isolation. On pathology review by BG and
PO, there were 27 grade 3 BRCA1 tumours and one case of
pure DCIS. The BRCA2 tumours comprised 16 cases that
were grade 3 and six cases that were grade 2. Although this
re¯ects the previous high percentage of BRCA1 and
BRCA2 tumours of high grade, it was clearly important
to use as controls a group of tumours matched for grade.
We therefore took 72 grade-matched tumours from the
control group used by the Breast Cancer Linkage
Consortium (1997) for immunocytochemical analysis of
p53. These comprised seven grade 2, 64 grade 3 and one
pure DCIS of comedo type. In addition to the selection of
these tumours on the basis of grade, it was possible to
assess whether they were biologically representative of
sporadic tumours of the designated grade on the basis of
published data for expression of p27Kip1 (Fredersdorf et al.,
1997) and the oestrogen receptor. These analyses con®rmed
that the control sporadic tumours were representative of
their allocated grade. All tumour grading was carried out
using the recommendations of the National Co-ordinating
Group for Breast Cancer Screening Pathology. For
sequencing, 20 of the control grade 3 tumours were
selected for DNA isolation and subsequent SSCP and
sequencing analysis. Proliferation was assessed by counting
the number of mitotic ®gures per 10 high-powered ®elds,
using the methodology advised by the National Co-
ordinating Group for Breast Screening Pathology.
Immunocytochemistry
Formalin-®xed, paran-embedded 5 mm sections were
mounted on glass slides then deparanized by passage
through graded alcohols. Following microwave antigen
retrieval, immunocytochemisty was performed as follows:
For p53: antibody DO-1 (purchased from Oncogene
Science) was diluted 1 : 1000 then applied to sections. For
P21Waf1: Tissue culture supernatant containing antibody
SX21 (Fredersdorf et al., 1996) was applied directly to
sections. The detection system used a biotinylated rabbit
anti-mouse polyclonal serum (Dako Cat. No. E0354) at
1 : 200 dilution, followed by a streptAB complex/HRP
(Dako. Cat. No. K0377) according to the manufacturer's
instructions.
p53 and p21Waf1 scoring
Each tumour was evaluated by two breast pathologists (PO
and BAG) without prior knowledge of the patient group.
Sections were scored for immunocytochemical positivity
using the `quick score' method (Detre et al., 1995). This
combines both intensity of staining (scored 0 ± 3), multi-
plied by the percentage of tumour cells positive (on a scale
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1 ± 6) giving a range of 1 ± 18 (within which range tumours
were designated positive).
Analysis of gene sequence
DNA was isolated from paran-embedded tissue following
xylene dewaxing by incubation for 5 days in SDS/
proteinase K at 558C. DNA was recovered by phenol
extraction and ethanol precipitation. For analysis of
mutation in exons 2 ± 11 of p53, SSCP was performed as
described (Visscher et al., 1996). Brie¯y, 50 ng of genomic
DNA was subjected to PCR in a total volume of 50 ml
containing 61 PCR buer (10 mM Tris.Cl, pH 8.3, 50 mM
KCl, 1.5 mM MgCl2 and 0.01% gelatin), 200 mM each
dNTP, 0.4 mM primers, 4 mCi a-32P dCTP and 2 units
AmpliTaq DNA polymerase (Cetus). Ampli®ed products
were denatured, then resolved on 5 or 6% native
polyacrylamide gels with and without 10% glycerol.
DNA samples with apparently abnormally migrating
conformers were reampli®ed, then ligated into pGEM-T.
Multiple plasmid clones were sequenced using T7 DNA
polymerase. Proposed mutations were sequenced on both
strands and from at least two paran sections. In view of
the high frequency of p53 mutations in the BRCA-
associated tumours suggested by initial SSCP analysis,
the coding sequence of p53 was determined in its entirety
for each tumour (irrespective of the presence of SSCP
shifts). At least 12 clones from each exon for each tumour
were sequenced to exclude the possible presence of p53
mutations which were not detected by SSCP. For analysis
of p16INK4, SSCP was performed using the PCR primers
and conditions described by Zhang et al. (1994). Following
PCR, ampli®ed products were resolved on 6% native
polyacrylamide gels. All reactions were run on gels with
5% glycerol (in 0.56 TBE) and 10% glycerol (in 16
TBE). Each gel run included positive control DNA samples
known to contain point mutations in the region of p16
under analysis. To verify absence of mutations, the
sequence of exons 1 and 2 of p16 was determined in 24
tumours (12 BRCA1 and 12 BRCA2). Sequencing
templates were generated by asymmetric PCR and
sequenced in both directions. For analysis of Ki-ras, a
106 bp region of the gene spanning codons 12 and 13 was
ampli®ed with the following primers: 5'-GACTGAATA-
TAAACTTGTGG-3' (sense) and 5'-CTATTGTTGGAT-
CATATTCG-3' (anti-sense). Reactions were performed in
61 reaction buer (60 mM KCl, 15 mM Tris pH 8.8,
2.2 mM MgCl2 200 mM of each dNTP, 20 pmol each
primer and 1 U Taq DNA polymerase. Reactions were
cycled 40 times at 948C (1 min), 558C (2 min) and 728C
(1 min). Ampli®ed products were resolved on 1.5% agarose
TAE gels, excised and puri®ed using a Qiaex II gel
extraction system, then ligated into pGEM T-easy and
sequenced. The presence of sequence changes in a 268 bp
fragment of b-globin was tested by SSCP using PCR
conditions previously described (Bauer et al., 1991).
Analysis for the presence of MSI-associated frameshift
mutations in the coding regions of TGF bRII [poly(A)10]
tract and Bax [poly(G)8] tract was performed as described
previously by Chung et al. (1997).
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